Polaris Venture Management Co. V

Latest statistics and disclosures from Polaris Venture Management Co. V's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are LYRA, XFOR, Atyr Pharma Inc Common Stock Usd 0.001, Dare Bioscience, GNCAQ, and represent 97.96% of Polaris Venture Management Co. V's stock portfolio.
  • Reduced shares in these 1 stock: FATE (-$50M).
  • Sold out of its position in FATE.
  • Polaris Venture Management Co. V was a net seller of stock by $-50M.
  • Polaris Venture Management Co. V has $14M in assets under management (AUM), dropping by -77.43%.
  • Central Index Key (CIK): 0001439589

Tip: Access up to 7 years of quarterly data

Positions held by Polaris Venture Management Co. V consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Polaris Venture Management Co. V

Polaris Venture Management Co. V holds 6 positions in its portfolio as reported in the September 2021 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Lyra Therapeutics Common Stock (LYRA) 71.3 $10M 1.1M 9.12
 View chart
x4 Pharmaceuticals Common Stock (XFOR) 11.7 $1.6M 312k 5.29
 View chart
Atyr Pharma Common Stock 8.4 $1.2M 131k 9.08
 View chart
Dare Bioscience Common Stock 3.9 $545k 326k 1.67
 View chart
Genocea Biosciences Common Stock (GNCAQ) 2.7 $379k 197k 1.92
 View chart
Pulmatrix Common Stock 2.0 $288k 359k 0.80
 View chart

Past Filings by Polaris Venture Management Co. V

SEC 13F filings are viewable for Polaris Venture Management Co. V going back to 2014

View all past filings